





Robert Greene Sterne lorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Michael B. Ray Robert E. Sokohl Michael O. Lee Steven R. Ludwig John M. Covert rt C. Millonig Donald L Featherstone Timothy J. Shea, Jr Michael V. Messinger Patrick F. Garrett

Jeffrey T. Helvey Eldora L. Ellison Thomas C Fiala Donald R. Banowit Peter A. Jackman Jeffrey S. Weaver Brian J. Del Buono Mark Fox Evens Edward W. Yee Vincent L. Capuano Virgil Lee Beaston Theodore A. Wood Elizabeth 1 Haanes Joseph S. Ostroff Frank R. Cottingham Daniel A. Klein Jason D. Eisenberg Michael D. Specht

Tracy L. Muller Jon E. Wright LuAnne M. DeSantis Ann E. Summerfield Helene C. Carlson Cynthia M. Bouchez Timothy A. Doyle Gaby L. Longsworth Lori A. Gordon Laura A. Vogel Bryan S. Wade Bashir M.S. Ali Shannon A. Carroll Anbar F. Khal Michelle K. Holoubek Marsha A. Rose Young Tang Christopher J. Walsh

W. Blake Coblentz James J. Pohl* John T. Haran Kevin W. McCabe Michael R. Malek

Registered Patent Agents Karen R. Markowicz Matthew I Dowd Katrina Yujian Pei Quach Bryan L. Skelton Robert A. Schwartzman Victoria S. Rutherford Simon J. Elliott tulie A. Heider Mita Mukherjee

Lifiana Di Nola-Raron Peter A. Socarras Jeffrey K. Mills Danielle L. Lettino Lori Brandes Steven C. Oppenheimer

Of Counsel Edward 1. Kessler Kenneth C. Bass III Marvin C. Guthrie

Admitted only in Maryland * Admitted only in Virginia Practice Limited to Federal Agencies

September 15, 2006

WRITER'S DIRECT NUMBER: (202) 772-8782 **INTERNET ADDRESS:** BCOBLENT@SKGF.COM

Art Unit 1645

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application No. 10/521,010

U.S. National Phase of Appl. No. PCT/AU2003/000910

Int'l Filing Date: July 14, 2003

For: **Expression of Hydrophobic Proteins** Inventors: Elizabeth Ann WEBB et al.

Our Ref:

2349.0010000/ΠJK/WBC

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Information Disclosure Statement Filing under 37 C.F.R. § 1.97(b);
- 2. Form PTO/SB/08A (1 page) citing seven (7) documents (US1 and FP1-FP6);
- 3. Copies of six (6) cited documents (FP1-FP6);
- 4. Form PTO/SB/08B (1 page) citing four (4) documents (NPL1-NPL4);
- 5. Copies of four (4) cited documents (NPL1-NPL4); and
- 6. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents September 15, 2006 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

William B. Coblentz

Attorney for Applicants Registration No. 57,104

JUK/WBC:cpn Enclosures



n re application of:

Elizabeth Ann WEBB et al.

Appl. No.: 10/521,010

Int'l Filing Date: July 14, 2003

For: Expression of Hydrophobic

Proteins

Confirmation No.: 2794

Art Unit: 1645

Examiner: To Be Assigned

Atty. Docket: 2349.0010000/JUK/WBC

Information Disclosure Statement Filing under 37 C.F.R. § 1.97(b)

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Forms PTO/SB/08A and PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents **FP1-FP6** and **NPL1-NPL4** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), a copy of the U.S. patent, document **US1**, cited on the attached Form PTO/SB/08A is not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return copies of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

William B. Coblentz Attorney for Applicants Registration No. 57,104

Date: September 15, 2006

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

530481_1.DOC

Equivalent of Form PTO/SB/08A (07-05) Approved for use through 07/31/2006.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute	VETER	449/PT()	Complete	Complete if Known		
				Application Number	10/521,010		
INFO	RMA'	TION	DISCLOSURE	Int'l Filing Date	July 14, 2003		
STAT	EME	NT BY	APPLICANT	First Named Inventor	Elizabeth Ann WEBB		
			ets as necessary)	Art Unit	To Be Assigned		
				Examiner Name	To Be Assigned		
Sheet	1	of	1	Attorney Docket Number	2349.0010000/JUK/WBC		

U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	110.	Number-Kind Code ^{2 (If Known)}		Applicant of Cited Document			
	USI	6,070,126	05/30/2000	Kokolus et al.			
					 		
	<u> </u>		-				
· · · · · · ·			 -				
		<u> </u>					
			 				

		Fo	REIGN PATENT DO	OCUMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or	
					Relevant Figures Appear	T6
	FP1	WO 96/03144 A1	02/08/1996	The Council of the Queensland Institute of Medical Research et al.		
	FP2	WO 97/05164 A1	02/13/1997	CSL Limited et al.		
	FP3	WO 99/55730 A1	11/04/1999	Chiron S.P.A., et al		
	FP4	WO 00/63693 A1	10/26/2000	Kokolus		\Box
	FP5	WO 01/19408 A1	03/22/2001	Zycos Inc., et al		П
	FP6	WO 01/47541 A1	07/05/2001	Epimmune, Inc., et al.		
			-			Н

530487_1:DOC

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

English language I ranslation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you pend assistance in completion of the page of the Patent of the Patent Selection of the Patent Selection

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE pond to a collection of information unless it contains a valid OMB control number.

Substitute for	form 1449/PT0)		Complete if Known		
				Application Number	10/521,010	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Int'l Filing Date	July 14, 2003	
				First Named Inventor	Elizabeth Ann WEBB	
(Use as many sheets as necessary)				Art Unit	To Be Assigned	
		Examiner Name	To Be Assigned			
Sheet	1	of	1	Attorney Docket Number	2349.0010000/JUK/WBC	

		NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²					
	NPL1	Deavin, A.J., et al., "Statistical Comparison of Established T-Cell Epitope Predictors Against a Large Database of Human and Murine Antigens," Mol. Immunol. 33:145-155, Elsevier Science Ltd. (1996)						
	NPL2	Firat, H., et al., "Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV-1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice," Eur. J. Immunol. 31:3064-3074, Wiley-VCH Verlag GmbH (October 2001)						
	NPL3	Le, T.T.T., et al., "Cytotoxic T cell polypeptide vaccines delivered by ISCOMSs," Vaccine 19:4669-4675, Elsevier Science Ltd. (September 2001)						
	NPL4	Shi, Y.P., et al., "Development, expression, and murine testing of a multistage Plasmodium falciparum malaria vaccine candidate," <i>Vaccine 18</i> :2902-2914, Elsevier Science Ltd. (2000)						
٠								

530488 1.DOC

	W. Chroling and Development Community of the Community of		
Examiner	/IVIICnaer Borni/	Date	
Signature		Considered	07/18/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.